Celecoxib versus diclofenac in the management of osteoarthritis of the knee: A placebo-controlled, randomised, double-blind comparison

Reference

• Hochberg MC, Altman RD, Brandt KD, Clark BM, Dieppe PA, Griffin MR, et al. Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. Arthritis Rheum 1995;38:1541–6.
   PubMed Web of Science ®Google Scholar
• Wolfe F, Zhao S, Lane N. Preference for NSAIDs over acetaminophen by rheumatic disease patients: a survey of 1799 patients with OA, RA, and fibromyalgia. Arthritis Rheum 2000;43: 378–85.
   Google Scholar
• Pincus T, Koch G, Sokka T, Wolfe F, Cummins P, Weaver A, et al. Diclofenac/misoprostol (Arthrotec) compared to acetaminophen (ACTA): a clinical trial in patients with osteoarthritis (OA) of the hip or knee [abstract]. Ann Rheum Dis 2000;59 Suppl. 1:276.
   Google Scholar
• Wolfe MM, Lichenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Eng J Med 1999;240:1888–99.
   Google Scholar
• Singh G. Recent considerations in nonsteroidal anti-inflam-matory drug gastropathy. Am J Med 1998;105 Suppl. 1B:31S–8S.
   Google Scholar
• Langman MJ, Weil J, Wainwright P, Lawson DH, Rawlins MD, Logan RF, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343:1075–8.
   PubMed Web of Science ®Google Scholar
• Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: a meta analysis. Ann Intern Med 1991;115:787–96.
   Google Scholar
• Barrier CH, Hirschowitz BI. Controversies in the detection and management of nonsteroidal antiinflammatory drug induced side effects of the upper gastrointestinal tract. Arthritis Rheum 1989;32:926–32.
   PubMed Web of Science ®Google Scholar
• Scholes D, Stergachis A, Penna PM, Normand EH, Hansten PD. Nonsteroidal antiinflammatory drug discontinuation in patients with osteoarthritis. J Rheumatol 1995;22:708–12.
   Google Scholar
• Bensen WG, Zhao SZ, Burke TA, Zabinski RA, Makuch RW, Maurath CJ, et al. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo. J Rheumatol 2000;27:1876–83.
   PubMed Web of Science ®Google Scholar
• Singh G, Ramey DR. NSAID induced gastrointestinal complications: the ARAMIS perspective - 1997. J Rheumatol 1998;25 Suppl. 51:8–16.
   Google Scholar
• Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci 1999;96:7563–68.
   PubMed Web of Science ®Google Scholar
• Vane J. Towards a better aspirin. Nature 1994;367:215–6.
   PubMed Web of Science ®Google Scholar
• Masferrer JL, Zweifel BS, Manning PT, Hauser SD, Leahy KM, Smith WG, et al. Selective inhibition of inducible cyclooxygenase 2 in vivo is anti-inflammatory and nonulcero-genic. Proc Natl Acad Sci USA 1994;91:3228–32.
   PubMed Web of Science ®Google Scholar
• Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins W, Docter S, et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: iden-tification of 445-(4-methylpheny1)-3-(trifluoromethyl)-1H-pyr-azol-1-yl] benzenesulfonamide (SC-58635, celecoxib). J Med Chem 1997;40:1347–65.
   PubMed Web of Science ®Google Scholar
• Simon LS, Lanza FL, Lipsky PE, Hubbard RC, Talwalker S, Schwartz BD, et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum 1998;41:1591–602.
   PubMed Web of Science ®Google Scholar
• Brooks P, Emery P, Evans JF, Fenner H, Hawkey CJ, Patrono C, et al. Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygen-ase-2. Rheumatology 1999;38:779–88.
   PubMed Web of Science ®Google Scholar
• Leese PT, Hubbard RC, Karim A, Isakson PC, Yu SS, Geis GS. Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial. J Chin Pharmacol 2000;40:124–32.
   Google Scholar
• Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RC, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 1999;282:1921–8.
   PubMed Web of Science ®Google Scholar
• Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al. Development of criteria for the classification and reporting of osteoarthritis of the knee. Diagnostic and therapeutic criteria committee of the American Rheumatism Association. Arthritis Rheum 1986;29:1039–49.
   PubMed Web of Science ®Google Scholar
• Bensen WG, Fiechtner JJ, McMillen JI, Zhao WW, Yu SS, Wood EM, et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin Proc 1999;74:1095–105.
   PubMed Web of Science ®Google Scholar
• Lequesne MG, Mery C, Samson M, Gerard P. Indexes of severity for osteoarthritis of the hip and knee. Validation-value in comparison with other assessment tests. Scand J Rheumatol 1987;16 Suppl 65:85–9 (Published corrections: Errata Scand J Rheumatol 1988; 17: 242 and Scand J Rheumatol 1988; 17 Suppl 73: 1).
   Google Scholar
• Langley GB, Sheppeard H. Problems associated with pain measurement in arthritis: comparison of visual analogue and verbal rating scales. Clin Exp Rheumatol 1985;2:231–4.
   Google Scholar
• Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stini LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to anti-rheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988;15:1833–40.
   Google Scholar
• Cooperating Clinics Committee of the American Rheumatism Association. A seven day variability study of 499 patients with peripheral rheumatoid arthritis. Arthritis Rheum 1965;8: 302–34.
   PubMed Web of Science ®Google Scholar
• Bellamy N. WOMAC Osteoarthritis Index: a user's guide. The Western Ontario and McMaster Universities, London, Ontario, 1995.
   Google Scholar
• American Pain Society Quality of Care Committee. Quality Improvement Guidelines for the Treatment of Acute Pain and Cancer Pain. JAMA 1995;274:1874–80.
   PubMed Web of Science ®Google Scholar
• Williams GW, Etlinger RE, Ruderman EM, Hubbard RC, Lonien ME, Yu SS, et al. Treatment of osteoarthritis with a once-daily dosing regimen of celecoxib: a randomized, controlled trial. J Clin Rheumatol 2000;6:65–74.
   PubMed Web of Science ®Google Scholar
• Zhao SZ, McMillen JI, Markenson JA, Dedhiya SD, Zhao WW, Osterhaus JT, et al. Evaluation of the functional status aspects of health-related quality of life of patients with osteoarthritis treated with celecoxib. Pharmacotherapy 1999;19:1269–78.
   PubMed Web of Science ®Google Scholar
• Hubbard RC, Geis GS, Woods EM, Yu S, Zhao W. Efficacy and tolerability of celecoxib, a COX-2 specific inhibitor, for treating the pain and inflammation of osteoarthritis. Proceed-ings of the 18th Annual Meeting of the American Pain Society. 1999 October 21–24, Fort Lauderdale (FL), 613.
   Google Scholar
• Geis GS, Hubbard RC, Yu S, Zhao W. Efficacy and tolerability of celecoxib: a comparison of once-daily vs twice-daily dosing [abstract]. Arthritis Rheum 1999;42 Suppl 9:S144.
   Google Scholar
• Zhao SZ, Dedhiya SD, Verburg K, Osterhaus JT. Celecoxib 200 mg administered once-a-day or in split doses has equal impact on health-related quality of life (HROOL) of patients with osteoarthritis (OA) [abstract]. Arthritis Rheum 1999;42 Suppl 9:S297.
   Google Scholar
• Zhao SZ, Yu SS, Dedhiya SD, Zhao WW, Osterhaus JT. Celecoxib improves health-related quality of life in patients with osteoarthritis of the knee [abstract]. Pharmacotherapy 1999;19:495.
   Google Scholar
• Emery P, Zeidler H, Kvien TK, Guslandi M, Naudin R, Stead H, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 1999;354:2106–11.
   PubMed Web of Science ®Google Scholar
• Goldstein JL, Silverstein FE, Agrawal NM, Hubbard RC, Kaiser J, Maurath CJ, et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 2000;95:1681–90.
   PubMed Web of Science ®Google Scholar
• Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. JAMA 2000;284:1247–55.
   PubMed Web of Science ®Google Scholar
• Bjarnason I, Macpherson AJ. Intestinal toxicity of non-steroidal anti-inflammatory drugs. Pharmacol Ther 1994;62:145–57.
   PubMedGoogle Scholar
• Maddrey WC, Maurath CJ, Verburg KM, Geis GS. The hepatic safety and tolerability of the novel cyclooxygenase (COX)-2 inhibitor celecoxib. Am J Ther 2000;7:153–8.
   PubMedGoogle Scholar
• Whelton A, Schulman G, Wallemark C, Drower EJ, Isakson PC, Verburg KM, et al. Effects of celecoxib and naproxen on renal function in the elderly. Arch Intern Med. 2000;160:1465–70.
   PubMed Web of Science ®Google Scholar
• Whelton A, Maurath CJ, Verburg KM, Geis GS. Renal safety and tolerability of celecoxib, a novel cyclooxygenase (COX-2) inhibitor. Am J Ther 2000;7:159–75.
   PubMedGoogle Scholar